Atomwise is a private company building in biotechnology / ai drug discovery, founded in 2012. The latest valuation stands at $320M. No public ticker exists for the company.
One company valuation: $320M.
DCVCLEADBB Capital GroupLEAD
Sanabil InvestmentsLEAD
Google Ventures
Khosla VenturesDCVCB Capital GroupSanabil InvestmentsAtomwise, now operating as Numerion Labs, is an AI-powered drug discovery company headquartered in San Francisco. Its AtomNet platform is a deep convolutional neural network trained on millions of structure–activity data points to predict how small molecules bind to protein targets, helping pharmaceutical and agrochemical partners screen candidates for diseases such as leukaemia, Ebola and multiple sclerosis.
Atomwise has worked on 750 research collaborations, modeled more than 600 disease targets, and virtually screened over 16 billion molecules.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Atomwise.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Atomwise availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Atomwise included.
No. Atomwise is a private company; its shares do not trade on a public exchange.
The last valuation is $320M.
Lead investors for each round are in the funding timeline.
The closest biotechnology / ai drug discovery peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
